TY - JOUR AU - L Laurenti, AU - P Piccioni, AU - M Tarnani, AU - DG Efremov, AU - A Fiorini, AU - M Garzia, AU - S Sica, PY - 2005/08/01 Y2 - 2024/03/29 TI - Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience JF - Haematologica JA - haematol VL - 90 IS - 8 SE - Letters to the Editor DO - 10.3324/%x UR - https://haematologica.org/article/view/3641 SP - 1143-1145 AB - We report the efficacy and safety of intravenous low-dose alemtuzumab (10 mg three times weekly for 10 weeks) in 12 patients with relapsed or refractory chronic lymphocytic leukemia. Low-dose alemtuzumab induced significant responses in these patients (16% complete remission, 25% partial remission), with mild hematologic and extrahematologic side effects and a low rate of infections, even in the presence of long-lasting severe immunosuppression. ER -